Terms: = Liver cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
61 results:
1. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
3. Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of cyp2d6 by dacomitinib.
Qiu X; Ren B; Lian Y; Fang L; Dong Z
J Oncol Pharm Pract; 2023 Jun; 29(4):1002-1005. PubMed ID: 36380705
[TBL] [Abstract] [Full Text] [Related]
4. Association of genetic polymorphisms of CYP3A4 and cyp2d6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract] [Full Text] [Related]
5. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.
Qiao F; Chen Q; Lu W; Fang N
Medicine (Baltimore); 2022 Jul; 101(27):e29629. PubMed ID: 35801736
[TBL] [Abstract] [Full Text] [Related]
6. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract] [Full Text] [Related]
7. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
[TBL] [Abstract] [Full Text] [Related]
8. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract] [Full Text] [Related]
9. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives.
Cura Y; Pérez Ramírez C; Sánchez Martín A; Martínez Martínez F; Calleja Hernández MÁ; Ramírez Tortosa MDC; Jiménez Morales A
Mutat Res Rev Mutat Res; 2021; 788():108391. PubMed ID: 34893156
[TBL] [Abstract] [Full Text] [Related]
10. Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity.
Khamis ZI; Pang X; Cui Z; Sang QA; Zhang J
PLoS One; 2021; 16(10):e0257072. PubMed ID: 34597305
[TBL] [Abstract] [Full Text] [Related]
11. Impact of cyp2d6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract] [Full Text] [Related]
12. Effects of dacomitinib on the pharmacokinetics of poziotinib
Ji W; Shen J; Wang B; Chen F; Meng D; Wang S; Dai D; Zhou Y; Wang C; Zhou Q
Pharm Biol; 2021 Dec; 59(1):457-464. PubMed ID: 33899675
[TBL] [Abstract] [Full Text] [Related]
13. An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib.
Wang C; Ying L; Jin M; Zhang F; Shi D; Dai Y; Zhou Z
Cancer Chemother Pharmacol; 2021 Jan; 87(1):43-52. PubMed ID: 33170322
[TBL] [Abstract] [Full Text] [Related]
14. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract] [Full Text] [Related]
15. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.
Zhao C; Hao H; Zhao H; Ren W; Jiao Y; An G; Sun H; Han S; Li P
J Ethnopharmacol; 2020 Jun; 255():112770. PubMed ID: 32205262
[TBL] [Abstract] [Full Text] [Related]
16. Human cyp2d6 Is Functional in Brain In Vivo: Evidence from Humanized cyp2d6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract] [Full Text] [Related]
17. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract] [Full Text] [Related]
18. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract] [Full Text] [Related]
19. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro.
Weissenstein U; Kunz M; Oufir M; Wang JT; Hamburger M; Urech K; Regueiro U; Baumgartner S
BMC Complement Altern Med; 2019 Jan; 19(1):23. PubMed ID: 30658716
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450.
Bao SS; Wen J; Zheng X; Zhou Q; Qu GE; Chen MJ; Hu GX
Toxicol Lett; 2018 Nov; 297():1-7. PubMed ID: 30138636
[TBL] [Abstract] [Full Text] [Related]
[Next]
